Health Care • Biotechnology: Pharmaceutical Preparations
$6.89 ▼ -0.24
(-3.37%)
MKT CAP: $891.8M • VOL: 2.74M
52W L $4 52W H $31
ALMS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $24.1M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$453.8M | -$300.8M | -$158.2M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$243.3M | -$294.2M | -$155.0M |
| EBITDA (Normalized) | -$453.3M | -$299.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$369.5M | -$255.1M | -$130.0M |
| Capital Expenditures (CapEx) | $653.0K | $1.7M | — |
| Free Cash Flow (FCF) | -$370.2M | -$256.8M | -$130.0M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $89.7M | $169.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $301.3M | $260.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALMS.